Short Term Effect of Empagliflozin in Hypertension

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yaounde Central Hospital
• Treatments: Empagliflozin

Criteria

Inclusion Criteria:

• Grade 1 hypertension

• Grade 1 or 2 relaxation abnormalities (Doppler E/A ratio <1)

• Unchanged antihypertensive treatment for at least 12 weeks

Exclusion Criteria:

• Diabetes mellitus

• eGFR < 60 mL/min/1,73 m²

• Mitral stenosis

• Atrial fibrillation

• Alanine transferase above 2N